Valeant Pharmaceuticals Intl Inc (VRX) Director Purchases C$481,500.00 in Stock

Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) Director Joseph Papa acquired 30,000 shares of Valeant Pharmaceuticals Intl stock in a transaction on Tuesday, March 13th. The shares were purchased at an average cost of C$16.05 per share, for a total transaction of C$481,500.00.

VRX stock opened at C$19.73 on Friday. Valeant Pharmaceuticals Intl Inc has a twelve month low of C$11.20 and a twelve month high of C$30.56.

How to Become a New Pot Stock Millionaire

Valeant Pharmaceuticals Intl (TSE:VRX) (NYSE:VRX) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported C$1.24 earnings per share for the quarter, meeting the Zacks’ consensus estimate of C$1.24. The company had revenue of C$2.75 billion for the quarter, compared to the consensus estimate of C$2.73 billion. Valeant Pharmaceuticals Intl had a return on equity of 112.73% and a net margin of 58.58%.

TRADEMARK VIOLATION WARNING: “Valeant Pharmaceuticals Intl Inc (VRX) Director Purchases C$481,500.00 in Stock” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with's FREE daily email newsletter.

Leave a Reply